Corona Genome Sequencing: Start-up "nanozoo" Launches Portal for Free Data Analysis
The central German start-up company "nanozoo" – a member of the InfectoGnostics research campus in Jena – has launched a portal for the free analysis and processing of raw data from the genome sequencing of SARS-CoV-2 isolates. Within a few hours, the data of registered users will be processed and made available. The resulting genome sequences are checked against the quality metrics defined by the Robert Koch Institute, which provide information on whether a data set meets the quality standards for submission to the federal institute.
The the portal nanozoo.cloud, which supports laboratories in processing raw data from "MinION" genome sequencing. With a subsequent update, "Illumina" data can also be analysed. For raw data from sequencing of SARS-CoV-2 samples, the service is provided free of charge for registered users from Germany. "For us, this is an opportunity to stress test our newly developed portal and at the same time contribute to the fight against the Corona pandemic. For the laboratories, on the other hand, an otherwise very time-consuming, manual step to a usable result is eliminated," explains Dr. Christian Brandt, molecular biologist at the Institute for Infectious Medicine and Hospital Hygiene at the Jena University Hospital and one of the three company founders.
The complete analysis and processing of the raw data takes – depending on the size of the data set – only between 30 minutes and a few hours. The data continues to belong completely to the submitting users and can then be transmitted independently to the RKI. Due to the danger of unrecognised corona mutations, on 18 January the German government called for the submission of genome sequence data from patient samples that had tested positive for SARS-CoV-2 and offered a payment of 220 euros per sequencing if the genome quality was good enough. For this purpose, nanozoo has also integrated a quality metric into the portal that provides information on whether the data meet the RKI quality standards and are suitable for transmission.
In addition, the three entrepreneurs, together with other partners from Berlin, Jena and Bad Langensalza, were involved in a current, pre-published study in which the SARS-CoV-2 genome from Thuringian samples was compared with virus lines spread in Germany, Europe and worldwide.
- genome sequencing
- genome sequences
- 1Detect neurodegenerative diseases such as Alzheimer's by a simple eye scan?
- 2Fluorescence microscopy at highest spatial and temporal resolution
- 3The Mechanics of the Immune System
- 4Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis
- 5Quick look under the skin
- 6New ion trap to create the world's most accurate mass spectrometer
- 7How does your computer smell?
- 8Clocking electron movements inside an atom
- 9Sartorius closes 2020 with strong growth
- 10A clear path to better insights into biomolecules
- Predicting the probability of death
- Many researchers are familiar with the problem: Before there are any new fin ...
- DZNE’s First Spin-off “Neuron–D” Uses Innovative Technology for Drug Testing
- Corona Genome Sequencing: Start-up "nanozoo" Launches Portal for Free Data A ...
- New and highly efficient method for SARS-CoV-2 mutation analysis